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Abstract
Background: Recently studies have demonstrated that the long non-coding RNA (lncRNA) metastasis associated
lung adenocarcinoma transcript 1 (MALAT1) may participate in the development and progression of lung cancer. In
this study, we hypothesized that genetic variant of this lncRNA may affect the prognosis of lung cancer patients.
Methods: We conducted a follow-up study for 538 patients with non–small cell lung carcinoma (NSCLC), including
140 early-staged (stage I and II) and 398 advanced staged (stage III and IV) patients. The genetic variant rs3200401
in MALAT1 was then genotyped among this population by using TaqMan assay. The association of this variant with
overall survival of these patients was further analyzed.
Results: It was shown that among the advanced lung adenoma patients, subjects carrying rs3200401 CT and
CT + TT genotypes had significantly longer median survival time (MST = 29.9, 28.9 vs. 19.3 month, Long-rank P = 0.
019 and 0.024, respectively) and decreased death risks [crude HR (95% CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95),
P = 0.040 and 0.025, respectively], when compared to subjects wtih the MALAT1 rs3200401 CC genotype. However,
the beneficial effect of rs3200401 was not seen among early NSCLC and advanced lung squamous cell carcinoma
patients. We further tested the TCGA data, and found that a higher expression of MALAT1 was associated with
metastatic of advanced lung adenocarcinoma but not with lung squamous cell carcinoma.
Conclusions: The rs3200401 T allele located on the lncRNA MALAT1 was associated with a better survival for
advanced lung adenocarcinoma patients, which may offer a novel prognostic biomarker for this patient subgroup.
However, these results need to be validated in larger populations of lung cancer and the biological function of this
variant still warrants further investigation.
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Background
Lung cancer was the most common cancer and one of the
leading cause of cancer-related death worldwide, and it
contributed to 13.0% of new cancer cases diagnosed in
2012 [1]. The non-small cell lung cancer (NSCLC) repre-
sents almost 85 to 90% of total diagnosed lung cancer,
while lung adenocarcinoma is the most common histo-
logical subtype. The 5-year survival rate of advanced
NSCLC is less than 5% based on the Surveillance, Epi-
demiology, and End Results (SEER) Program data [2].
Long non-coding RNAs are RNA genes larger than
200 bps, which do not code for proteins but regulate
gene expression and protein synthesis [3]. Several
lncRNAs were reported to be associated with tumori-
genesis, tumor progression, and tumor metastasis [4–7].
In general, most lncRNAs are expressed at low levels.
Metastasis associated lung adenocarcinoma transcript 1
(MALAT1), also known as noncoding nuclear-enriched
abundant transcript 2 (NEAT2), is one of the most
abundant and highly conserved lncRNAs, indicating its
potential functional importance [8]. MALAT1 is broadly
expressed in normal human tissues and overexpressed in
numerous cancers as well as NSCLC [9]. It has been
proposed that MALAT1 can regulate gene expression
and alternative splicing. MALAT1 is localized in nucleus
speckles at SRSF2 splicing domain in several cell lines
and can interact with pre-mRNA-splicing factor SF2/
ASF and CC3 antigen [10–14]. In vitro studies revealed
that MALAT1 can regulate cell proliferation, migration,
and vessel growth [15–17].
MALAT1 was originally identified as a marker for pre-
dicting metastasis and prognosis of early-staged NSCLC pa-
tients [9, 18]. Many researches also indicated that
MALAT1 is linked to other cancer types or diseases as a
negative prognosis factor, such as glioma, pancreatic cancer,
colorectal cancer, etc. [19–25]. However, the associations
between genetic polymorphisms of lncRNA MALAT1 and
lung cancer prognosis were less investigated.
In this study, we genotyped the single nucleotide poly-
morphism (SNP) rs3200401 located in lncRNA MALAT1
and aimed to investigate its association with the survival
outcome of 398 advanced NSCLC patients.
Methods
Study patients
The study enrolled 538 patients who were diagnosed as
NSCLC and treated at the Department of Oncology at
Wuhan Iron and Steel (Group) Corporation Staff-
Worker Hospital between January 2003 and December
2012. Patients who were still alive on December 31,
2013 (132 patients) were considered as censored, and
the survival time for each patient was calculated from
the date when they were confirmed diagnosed of lung
cancer until the date of death or the last follow-up. The
demographic data, lifestyle risk factors (e.g. smoking sta-
tus, drinking), medical history, and clinical features were
gathered by interview or from the patients’ medical re-
cords. A large part of study patients has been studied
and reported in our previous study [26].
SNP selection and genotyping
The NCBI dbSNP database were used to select the SNP
of MALAT1 (https://www.ncbi.nlm.nih.gov/snp/). It was
indicated by the dbSNP database that there are 16 SNPs
located on MALAT1 gene with the MAF > 0.01, how-
ever, only rs3200401 had the MAF > 0.10 in all the 1000
Genome, the NHLBI “Grand Opportunity” Exome Se-
quencing Project (GO-ESP), and Exome Aggregation
Consortium (ExAC) projects (https://www.ncbi.nlm.nih.-
gov/variation/view/) (Additional file 1: Table S1). Thus,
to acquire adequate statistical power, the SNP rs3200401
was investigated in the present study, while the other
SNPs with MAF < 0.10 were not selected. Genomic
DNA samples were extracted from blood cells by using
Gentra Puregene Blood Kit (QIAGEN, Hilden, Germany)
following manufacturer’s instructions. The MALAT1
polymorphism, rs3200401 C > T, was genotyped by Taq-
Man assay among all study subjects using ABI 7900HT
Sequence Detection System (Applied Biosystems,
Waltham, Massachusetts, USA) and each sample was
analyzed in duplicate. The primers and probes were
purchased from Life Technologies (Catalog No.
C___3246069_10). The genotyping call rate was 98.1%
and the concordance rate was 100%.
Statistical analysis
Kaplan-Meier analysis and log-rank test were used to as-
sess the associations between survival time and demo-
graphic characteristics, clinical features, and MALAT1
rs3200401 genotypes. We use dominant model to assess
the association of SNP rs3200401 genotypes and survival
outcome of early and advanced NSCLC patients, re-
spectively. The multivariate Cox regression models, with
adjustment for age, sex, smoking status, histology, TNM
stage, and therapy treatments of surgical resection,
chemotherapy, and radiotherapy, were used to estimate
the adjusted hazard ratio (HR) and 95% CIs for the effect
of MALAT1 rs3200401 genotypes on death risk for
NSCLC patients. All data analyses were performed in
SPSS software (version 22, IBM SPSS Statistics, IBM
Corporation, Chicago, IL). Power analysis was performed
by using Power and Sample Size version 13.2 application
in SAS (version 9.4, SAS Institute Inc., Cary, NC).
Results
Patient characteristics
The demographic information and clinical features for
NSCLC patients were presented in Table 1. Among
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these patients, a total of 78 early-staged and 328 ad-
vanced NSCLC patients were confirmed death of lung
cancer until the date of the last follow-up. Among these
NSCLC patients, there are 450 males (84%) and 88
(16%) females, with a median age of 66.5 years (range,
40–87). Log-rank test and univariate cox-regression
showed that NSCLC patients with age > 65, advanced
stage (stage III or IV), and without surgical treatment
had lower median survival time (MST) and higher death
risks than their counterparts (all log-rank P < 0.05).
However, there were no significant effects of smoking,
chemotherapy, and radiotherapy on the MST and death
risk of these NSCLC patients. The statistical power
analysis showed that, as for the SNP rs3200401
(MAF = 0.187) analyzed in this study, it had the
statistical power of 0.913 to detect the association
with HR= 1.4 by using 398 subjects in the survival analysis.
Patients with age > 65 or with advanced staging had a
significantly shorter survival time and higher risk of
death when comparing with patients with age ≤ 65 or
diagnosed at early stage [MST = 16.4 vs. 29.9 months,
log-rank P < 0.001, HR (95% CI) = 1.54 (1.27–1.88); MST =
17.9 vs. 57.6 months, log-rank P < 0.001, HR (95% CI) =
2.43 (1.89–3.12), respectively] (Table 1). In addition,
NSCLC patients who underwent surgical treatment had a
longer survival time and a lower risk of death [MST= 36.1
vs.17.6 months, log-rank P <0.01, HR (95% CI) = 0.53
(0.43–0.65)] (Table 1). However, there were no significant
associations of smoking status, chemotherapy, and radio-
therapy (all log-rank P > 0.05) with the survival outcomes
among NSCLC patients.
Association of genetic variant rs3200401 with survival
outcome among NSCLC patients
The associations between lncRNA MALAT1 rs3200401
genotypes and survival outcome of early-staged NSCLC
patients were shown in Table 2. No significant associa-
tions were found between rs3200401 genotypes and the
MST and death risk of early NSCLC patients, either in
adenocarcinoma or squamous cell carcinoma. (Table 2).
Among the advanced NSCLC patients, those carrying
MALAT1 rs3200401 CT and rs3200401 CT + TT
genotypes have significantly longer MST than those with
rs3200401 CC genotype (MST = 22.6, 21.8 vs.15.9 months,
and log-rank P = 0.045 and 0.034, respectively) (Table 3).
The univariate cox proportional hazard models showed
that, when compared to the rs3200401 CC genotype, the
rs3200401 CT and CT +TT genotypes were associated
with significant lower death risk for advanced NSCLC
patients [crude HR (95% CI) = 0.78 (0.61–0.99) and 0.78
(0.61–0.98), P = 0.046 and 0.034, respectively]. But after
adjusted by potential confounders, no statistically signifi-
cant associations were found between CT [adjusted HR
(95% CI) = 0.82 (0.64–1.05), P = 0.119] and CT + TT geno-
types [adjusted HR (95% CI) = 0.81 (0.64–1.04), P = 0.094]
with death risk of advanced NSCLC patients.
We further analyzed the associations of MALAT1
rs3200401 with survival outcomes among advanced
patients with lung adenocarcinoma and squamous cell
carcinoma separately (Table 3). Compared to advanced














≤65 253 (0.47) 178 29.9 — 1.00
(Reference)
>65 285 (0.53) 228 16.4 <0.001 1.54
(1.27–1.88)
Sex
Male 450 (0.84) 345 20.7 — 1.00
(Reference)
Female 88 (0.16) 61 28.9 0.042 0.75
(0.57–0.99)
Smoking
Never 93 (0.17) 65 30.5 — 1.00
(Reference)
Ever 445 (0.83) 341 21.1 0.11 1.24
(0.95–1.61)
Histology




188 (0.35) 143 28.1 0.81 1.03
(0.82–1.29)
Others 113 (0.21) 98 13.3 <0.01 1.74
(1.35–2.23)
Clinical Stage
Early 140 (0.26) 78 57.6 — 1.00
(Reference)
Advanced 398 (0.74) 328 17.9 <0.001 2.43
(1.89–3.12)
Surgery
No 334 (0.62) 281 17.6 — 1.00
(Reference)
Yes 204 (0.38) 125 36.1 <0.01 0.53
(0.43–0.65)
Chemotherapy
No 126 (0.23) 95 20.1 — 1.00
(Reference)
Yes 412 (0.77) 311 23.7 0.24 0.87
(0.69–1.1)
Radiotherapy
No 291 (0.54) 208 22.9 — 1.00
(Reference)
Yes 247 (0.46) 198 21.5 0.24 1.08
(0.89–1.31)
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lung adenocarcinoma patients carrying the rs3200401
CC genotype, those with rs3200401 CT and CT + TT
genotypes had significant longer MST and lower risk of
death (MST = 29.9 and 28.9 months vs. 19.3 months,
log-rank P = 0.019 and 0.024) [crude HR (95% CI) = 0.62
(0.41–0.93) and 0.65 (0.44–0.95); adjusted HR (95%
CI) = 0.65 (0.43–0.98) and 0.64 (0.44–0.95), respect-
ively] (Table 3) (Fig. 1a). However, this effect was not
seen among advanced lung squamous cell carcinoma
patients (Fig. 1b).
Stratified analysis for advanced NSCLC patients
We then stratified the advanced lung adenocarcinoma
and squamous cell carcinoma patients by age, sex,
smoking, TNM stage, surgical operation, chemo- or
radio-therapy, respectively (Table 4). We found the
rs3200401 CT + TT genotype was associated with a de-
creased death risk at a borderline significance among
lung adenocarcinoma patients with age ≤ 65 [HR (95%
CI) = 0.59 (0.35–1.00), P = 0.054]) and stage IIIA-IIIB [HR
(95% CI) = 0.54 (0.29–1.01), P = 0.053]. No significant
Table 2 Associations between LncRNA MALAT1 rs3200401 genotypes and survival of early-staged NSCLC patients
Genotypes Patients (%) Deaths MST (months) Log-rank P Crude HR (95% CI) Crude P Adjusted HR (95% CI)a Adjusted P
All patients
CC 86 48 55.3 – 1.00 (Reference) — 1.00 (Reference) —
CT 49 26 61.4 0.940 0.92 (0.57–1.48) 0.717 0.92 (0.56–1.51) 0.734
TT 3 2 39.2 0.980 1.15 (0.28–4.77) 0.848 1.07 (0.25–4.65) 0.929
CT + TT 52 28 61.4 0.760 0.93 (0.58–1.48) 0.756 0.93 (0.57–1.51) 0.760
Adenocarcinoma
CC 37 18 62.9 – 1.00 (Reference) — 1.00 (Reference) —
CT 18 6 — 0.650 0.65 (0.25–1.64) 0.357 0.42 (0.15–1.19) 0.104
TT 1 0 — — — — — —
CT + TT 19 6 — 0.290 0.61 (0.24–1.55) 0.297 0.40 (0.14–1.12) 0.082
Squamous cell carcinoma
CC 41 25 48.6 – 1.00 (Reference) — 1.00 (Reference) —
CT 26 16 57.6 0.920 0.88 (0.46–1.65) 0.683 0.81 (0.40–1.64) 0.563
TT 1 1 41.2 0.880 1.63 (0.22–12.23) 0.635 1.58 (0.17–14.49) 0.685
CT + TT 27 17 57.6 0.740 0.90 (0.48–1.68) 0.743 0.83 (0.42–1.66) 0.602
aAdjusted for age, sex, smoking status, surgery, chemotherapy and radiotherapy
Table 3 Associations between LncRNA MALAT1 rs3200401 genotypes and survival of advanced NSCLC patients
Genotypes Patients (%) Deaths MST (months) Log-rank P Crude HR (95% CI) Crude P Adjusted HR (95% CI)a Adjusted P
All patients
CC 259 (66.4) 219 15.9 — 1.00 (Reference) — 1.00 (Reference) —
CT 120 (30.8) 94 22.6 0.045 0.78 (0.61–0.99) 0.046 0.82 (0.64–1.05) 0.119
TT 11 (2.8) 8 21.8 0.353 0.71 (0.35–1.44) 0.345 0.73 (0.36–1.50) 0.392
CT + TT 131 (33.6) 102 21.8 0.034 0.78 (0.61–0.98) 0.034 0.81 (0.64–1.04) 0.094
Adenocarcinoma
CC 119 (68.4) 99 19.3 — 1.00 (Reference) — 1.00 (Reference) —
CT 48 (27.6) 31 29.9 0.019 0.62 (0.41–0.93) 0.020 0.65 (0.43–0.98) 0.040
TT 7 (4.0) 5 19.1 0.804 0.87 (0.36–2.15) 0.767 0.89 (0.35–2.24) 0.806
CT + TT 55 (31.6) 36 28.9 0.024 0.65 (0.44–0.95) 0.025 0.64 (0.44–0.95) 0.025
Squamous cell carcinoma
CC 76 (63.3) 62 17.9 — 1.00 (Reference) — 1.00 (Reference) —
CT 42 (35.0) 37 20.6 0.798 1.05 (0.70–1.59) 0.800 1.14 (0.75–1.75) 0.538
TT 2 (1.7) 2 11 0.999 1.01 (0.25–4.13) 0.992 1.46 (0.25–8.56) 0.676
CT + TT 44 (36.7) 39 20.6 0.805 1.05 (0.70–1.57) 0.805 1.05 (0.70–1.57) 0.805
aAdjusted for age, sex, smoking status, surgery, chemotherapy and radiotherapy
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associations between rs3200401 genotypes and survival
were seen among squamous cell carcinoma patients in
each stratum.
Discussion
In this follow-up study for case-only survival analysis,
we investigated the association of the genetic variation
rs3200401 in lncRNA MALAT1 with the survival out-
come of NSCLC patients. We found that among ad-
vanced lung adenocarcinoma patients, those carrying
MALAT1 rs3200401 CT or CT + TT genotypes had
significant longer survival time and decreased death
risks than those carrying rs3200401 CC genotype. This
finding suggested that rs3200401 C > T variant of
MALAT1 might be a potential prognostic biomarker for
predicting the survival of advanced lung adenocarcinoma
patients.
Metastasis is the major cause of death from lung can-
cer [27], and MALAT1 was significantly associated with
metastasis of early-stage NSCLC patients [9]. The
in vitro cell and in vivo animal studies had revealed that
the expression level of lncRNA MALAT1 is related to
cell migration potential and tumor growth. Increased
MALAT1 expression in tumor tissues of NSCLC pa-
tients is associated with an unfavorable overall survival
[19], while the high expression of MALAT1 in tumor
tissues was also found to be associated with an increased
risk of metastasis and a poor overall survival among
colorectal cancer [21], pancreatic cancer [22], glioma
[23], and clear cell renal cell carcinoma [24]. MALAT1
can induce metastasis through various mechanisms. The
in vitro siRNA-mediated MALAT1 silencing resulted in
impaired lung cancer cell motility by altering the expres-
sion levels of cell motility-related genes, such as HMMR
at pre-mRNA transcriptional level and CTHRC1, CCT4
and ROD1 at post-transcriptional level [15]. Inhibition
of MALAT1 was seen to have an anti-proliferative effect
and controls phenotypic switch in endothelial cells, indi-
cating that MALAT1 may regulate angiogenesis and re-
sult in metastasis [17, 28]. More researches suggested
that upregulated MALAT1 can induce an epithelial-to-
mesenchymal transition (EMT) and bladder cancer cell
migration [29] and promote brain metastasis [30].
Although MALAT1 expression in lung cancer tissue
was reported to be associated with poor prognosis in
lung squamous cell carcinoma [19], our findings indi-
cated that the SNP rs3200401 cannot affect the survival
outcome of lung squamous cell carcinoma patients. Ji
et al. found that the association of MALAT1 with metas-
tasis of NSCLC was distinct among different histological
Fig. 1 a Kaplan-Meier estimates for the overall survival of patients with advanced lung adenocarcinoma according to MALAT1 rs3200401 C > T.
b Kaplan-Meier estimates for the overall survival of patients with advanced lung squamous cell carcinoma according to MALAT1 rs3200401 C > T
Table 4 Stratified analysis of lncRNA MALAT1 rs3200401
genotypes associated with advanced NSCLC patients’ survival
Variables Adenocarcinoma Squamous cell carcinoma
Adjusted HR (95% CI)a
CT + TT vs. CC
Pa Adjusted HR (95% CI)a
CT + TT vs. CC
Pa
Age
≤65 0.59 (0.35–1.00) 0.054 1.32 (0.69–2.53) 0.397
>65 0.94 (0.51–1.74) 0.850 0.95 (0.53–1.69) 0.862
Sex
Male 0.66 (0.42–1.05) 0.081 1.04 (0.67–1.63) 0.857
Female 0.64 (0.26–1.54) 0.317 — —
Smoking
Never 0.44 (0.18–1.10) 0.079 16.73 (0.10–2963.81) 0.285
Ever 0.73 (0.46–1.15) 0.170 1.01 (0.65–1.60) 0.933
TNM Stage
IIIA-IIIB 0.54 (0.29–1.01) 0.053 1.08 (0.65–1.79) 0.779
IV 0.83 (0.48–1.41) 0.484 0.91 (0.42–1.96) 0.810
Surgical operation
No 0.69 (0.42–1.13) 0.137 0.99 (0.61–1.63) 0.982
Yes 0.56 (0.27–1.16) 0.118 1.12 (0.50–2.51) 0.792
Chemotherapy or Radiotherapy
No 0.47 (0.05–4.55) 0.516 4.73 (0.35–63.42) 0.241
Yes 0.71 (0.47–1.07) 0.098 1.07 (0.70–1.65) 0.753
aAdjusted for age, smoking, TNM stage, surgery, chemo- and radio-therapy
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subtypes: MALAT1 expression in metastatic lung adeno-
carcinoma was several fold higher than in non-metastatic
adenocarcinoma, but no significant differences were found
between metastatic and non-metastatic lung squamous
cell carcinoma patients [9]. We obtained the clinical data
and MALAT1 gene expression data from the cancer gen-
ome atlas (TCGA) using cBioPortal [31]. A total of 654
patients with primary lung cancer (359 lung adenocarcin-
oma and 295 lung squamous cell carcinoma) and available
MALAT1 expression data from white population were
included. Among them, a total of 117 patients were diag-
nosed at an advanced stage. The demographic data for
these advanced NSCLC patients was presented in
Additional file 1: Table S2. We found significant higher
MALAT1 expression levels in lung adenocarcinoma tissues
than in lung squamous cell carcinoma tissues (P <0.001,
Fig. 2a). In 75 tumors with advanced lung adenocarcinoma,
higher expression levels of MALAT1 were seen in tissues
from M1 or Mx patients than those from M0 patients (P =
0.049). However, this difference was not shown in 42
patients with advanced lung squamous cell carcinoma
(Fig. 2b). Considering the different characteristics of these
two major subtypes of NSCLC, the lncRNA MALAT1 may
induce tumor metastasis through different mechanisms
between adenocarcinoma and squamous cell carcinoma.
Regarding the biological function for lncRNA
MALAT1, it was found to localize to nuclear speckles
and interact with serine/arginine-rich (SR) proteins like
serine/arginine-rich splicing factor 1 (SRSF1), SRSF2
(SC35) and RNA-binding protein with serine-rich
domain 1 (RNPS1) that controls alternative splicing of
pre-mRNA, a transcriptional level regulation of gene ex-
pression [10, 13, 32–35]. Large studies have reported
that genetic polymorphisms on certain genes may affect
the susceptibility of lung cancer [36, 37], sensitivity of
chemo- or radiotherapy [38–40], and length of survival
or prognosis [41–44]. Liu et al. found a borderline sig-
nificant association between rs619586 in MALAT1 and
decreased hepatocellular carcinoma risk [45]. Another
study carried out by Gong et al. did not found any asso-
ciation between rs619586 genotype and lung cancer risk,
but patients with rs619586 A allele had more chance of
response to platinum-based chemotherapy [40]. In this
study, we did not investigate the rs619586 of MALAT1
because the dbSNP database suggested it is a low-
frequency SNP. Further studies with larger sample sized
populations could investigate the low-frequency SNPs of
MALAT1 with higher detection power, and the
biological functions for the positive variants of MALAT1
also warrant further deep investigation.
The interaction between lncRNA and other molecules
was probably determined by its structure rather than by
its sequence. The polymorphism within lncRNA
sequence may exert its function through alternative spli-
cing of the transcript or lncRNA secondary structure
change, resulting in gain or loss of function [46]. The
SNP rs3200401 C > T variant locates in the region M of
MALAT1 (6008–7011 nt), which is one of the binding
sites to SRSF2 [34]. We use lncRNASNP database to
predict potential functions of this SNP [47], such as
structure change and miRNA-lncRNA interaction. We
found that the C > T variation of rs3200401 caused
1.62 kcal/mol minimal free energy (MFE, ΔG) change,
which may alter structural features of MALAT1
(Additional file 2: Figure S1), resulting in weaken inter-
action between MALAT1 and its binding protein SRSF2.
MALAT1 can modulate phosphorylation of SRSF2,
interact with SR proteins as a “molecular sponge” and
influence their stability, and regulate the alternative spli-
cing of pre-mRNAs [10, 13]. SRSF2 and phosphorylated
SRSF2 were reported to correlate with aggressive
features of lung adenocarcinoma but not with lung squa-
mous cell carcinoma patients [48]. It was biologically
possible that SNP rs3200401 C > T variant may cause
MALAT1-SRSF2 binding loss, affect phosphorylation of
SRSF2, down-regulate phosphorylation of SRSF2, change
the alternative splicing of pre-mRNAs, and then alter
the expression levels of metastasis associated genes.
These effects may result in a lower aggressive feature
and a better survival for lung adenocarcinoma but not
for squamous cell carcinoma patients.
Although this is the first study to describe lncRNA SNP
and lung adenocarcinoma survival, some limitations should
Fig. 2 a. The different expression levels of MALAT1 between lung
adenocarcinoma and squamous cell carcinama tissues; b. differences
in tissues from M1 or Mx to M0 patients
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be taken into consideration. First, this study used a single-
institution cohort to investigate the association between
MALAT1 variant and the survival outcome of lung cancer
patients for practical reason. It would be ideal to have a
multi-center based replication to validate our findings.
Without such replication, our findings should be consid-
ered preliminary. Second, to get adequate statistical power
by using this moderate cohort of lung cancer patients, we
only choose the SNP with MAF > 0.1 (rs3200401) to inves-
tigate in the present study. The other low-frequency SNPs
in MALAT1 were also needed to be investigated in further
large sample-sized populations. Finally, it is a pity that there
were no rs3200401 genotype data in the TCGA database,
except for the expression of MALAT1 in lung tumor tis-
sues. To give a clue for further interpretation and explan-
ation of the biological function of rs3200401, we still
analyzed the TCGA data and found that a higher MALAT1
expression level was associated with a worse survival out-
come among advanced lung adenocarcinoma patients. But
the biological function of this SNP and its effect on
MALAT1 expression level need to be deep investigated by
further biological studies.
Conclusions
In conclusion, this study revealed that the genetic vari-
ation SNP rs3200401 T allele located on lncRNA
MALAT1 was associated with a better survival of ad-
vanced lung adenocarcinoma patient, while this effect
was not seen among lung squamous cell carcinoma
patients. The protective effect of rs3200401 T allele may
because it can influence the secondary structure of
lncRNA MALAT1, or influence the interaction between
MALAT1 and SR proteins thus by altering the expres-
sion levels of metastasis associated genes. The MALAT1
rs3200401 T allele may serve as a novel biomarker for
predicting clinical outcomes of lung adenocarcinoma.
Further large population based survival analysis and
mechanistic studies are required to confirm our findings.
Additional file
Additional file 1: Table S1. The SNPs located on the lncRNA MALAT1
gene (data source: the dbSNP database). Table S2. Demographic and clinical
characteristics of 117 advanced NSCLC patients from TCGA. (DOCX 24.8 kb)
Additional file 2: Figure S1. Predicted secondary structures of lncRNA
MALAT1. C > T variation of rs3200401 caused 1.62 kcal/mol minimal free
energy (MFE, ΔG) change, which may alter structural features of MALAT1,
resulting in weaken interaction between MALAT1 and its binding protein
SRSF2. (TIF 215 kb)
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